AAAAAA

   
Results: 1-12 |
Results: 12
Sequencing of protease inhibitor therapy: insights from an analysis of HIVphenotypic resistance in patients failing protease inhibitors
Authors: Kemper, CA Witt, MD Keiser, PH Dube, MP Forthal, DN Leibowitz, M Smith, DS Rigby, A Hellmann, NS Lie, YS Leedom, J Richman, D McCutchan, JA Haubrich, R
Citation: Ca. Kemper et al., Sequencing of protease inhibitor therapy: insights from an analysis of HIVphenotypic resistance in patients failing protease inhibitors, AIDS, 15(5), 2001, pp. 609-615
Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs
Authors: Dunne, AL Mitchell, FM Coberly, SK Hellmann, NS Hoy, J Mijch, A Petropoulos, CJ Mills, J Crowe, SM
Citation: Al. Dunne et al., Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs, AIDS, 15(12), 2001, pp. 1471-1475
Cerebrospinal fluid response to structured treatment interruption after virological failure
Authors: Price, RW Paxinos, EE Grant, RM Drews, B Nilsson, A Hoh, R Hellmann, NS Petropoulos, CJ Deeks, SG
Citation: Rw. Price et al., Cerebrospinal fluid response to structured treatment interruption after virological failure, AIDS, 15(10), 2001, pp. 1251-1259
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
Authors: Deeks, SG Wrin, T Liegler, T Hoh, R Hayden, M Barbour, JD Hellmann, NS Petropoulos, CJ McCune, JM Hellerstein, MK Grant, RM
Citation: Sg. Deeks et al., Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia., N ENG J MED, 344(7), 2001, pp. 472-480
Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: Identification and characterization of the source of exposure
Authors: Roland, ME Martin, JN Grant, RM Hellmann, NS Bamberger, JD Katz, MH Chesney, M Franses, K Coates, TJ Kahn, JO
Citation: Me. Roland et al., Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: Identification and characterization of the source of exposure, J INFEC DIS, 184(12), 2001, pp. 1608-1612
Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiencyvirus infection
Authors: Call, SA Saag, MS Westfall, AO Raper, JL Pham, SV Tolson, JM Hellmann, NS Cloud, GA Johnson, VA
Citation: Sa. Call et al., Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiencyvirus infection, J INFEC DIS, 183(3), 2001, pp. 401-408
Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients
Authors: Parkin, NT Deeks, SG Wrin, MT Yap, J Grant, RM Lee, KH Heeren, D Hellmann, NS Petropoulos, CJ
Citation: Nt. Parkin et al., Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients, AIDS, 14(18), 2000, pp. 2877-2887
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
Authors: Havlir, DV Hellmann, NS Petropoulos, CJ Whitcomb, JM Collier, AC Hirsch, MS Tebas, P Sommadossi, JP Richman, DD
Citation: Dv. Havlir et al., Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens, J AM MED A, 283(2), 2000, pp. 229-234
Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) frompatients with primary HIV infection to nonnucleoside reverse transcriptaseinhibitors is associated with variation at novel amino acid sites
Authors: Brown, AJL Precious, HM Whitcomb, JM Wong, JK Quigg, M Huang, W Daar, ES D'Aquila, RT Keiser, PH Connick, E Hellmann, NS Petropoulos, CJ Richman, DD Little, SJ
Citation: Ajl. Brown et al., Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) frompatients with primary HIV infection to nonnucleoside reverse transcriptaseinhibitors is associated with variation at novel amino acid sites, J VIROLOGY, 74(22), 2000, pp. 10269-10273
Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998
Authors: Weinstock, H Respess, R Heneine, W Petropoulos, CJ Hellmann, NS Luo, CC Pau, CP Woods, T Gwinn, M Kaplan, J
Citation: H. Weinstock et al., Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998, J INFEC DIS, 182(1), 2000, pp. 330-333
Reduced antiretroviral drug susceptibility among patients with primary HIVinfection
Authors: Little, SJ Daar, ES D'Aquila, RT Keiser, PH Connick, E Whitcomb, JM Hellmann, NS Petropoulos, CJ Sutton, L Pitt, JA Rosenberg, ES Koup, RA Walker, BD Richman, DD
Citation: Sj. Little et al., Reduced antiretroviral drug susceptibility among patients with primary HIVinfection, J AM MED A, 282(12), 1999, pp. 1142-1149
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
Authors: Deeks, SG Hellmann, NS Grant, RM Parkin, NT Petropoulos, CJ Becker, M Symonds, W Chesney, M Volberding, PA
Citation: Sg. Deeks et al., Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome, J INFEC DIS, 179(6), 1999, pp. 1375-1381
Risultati: 1-12 |